CURRENT TREATMENT PRACTICES AND THEIR EFFICACY AND SAFETY IN REFRACTORY OR SUPER-REFRACTORY STATUS EPILEPTICUS- A SYSTEMATIC REVIEW
Author(s)
Sharan N1, Srivastava K1, Akehurst R2, Erder H3, Strzelczyk A4, Bonthapally V5
1BresMed Health Solutions, Panjim, India, 2Bresmed Health Solutions, Sheffield, UK, 3M. H. Erder Health Economics, Livingston, NJ, USA, 4Goethe University, Frankfurt am Main, Germany, 5Sage Therapeutics, Inc., Cambridge, MA, USA
OBJECTIVES: To assess the efficacy and safety of treatments for refractory or super-refractory status epilepticus (RSE/SRSE). METHODS: The following databases were searched: Embase, Medline, Medline in-process, PsycINFO, Cochrane using keywords “'status epilepticus”, “epilepsy”, “seizure”, “random”, “cohort”, “observational”. Randomized controlled trials (RCTs), non-RCTs, and observational studies were included. RESULTS: Database searches (August 2015) retrieved 6751 citations. Of these, 912 full-texts were screened for eligibility, after which 156 were considered as eligible. After further screening, nine RCTs, 10 non-RCTs and 120 observational studies were extracted. Super-Refractory Status Epilepticus CONCLUSIONS: Findings suggest that there is no consensus for the management and definitions of RSE conditions. Agents such as valproate, propofol, midazolam and diazepam achieved good seizure control for RSE patients during continuous IV therapy but successful weaning from general anaesthetics has not been well studied. Well-designed prospective trials are needed to establish the efficacy and tolerability of RSE and SRSE treatments.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PND8
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Neurological Disorders